BeOne Medicines Ltd. – Sponsored ADR $ONC Shares Acquired by Fiera Capital Corp

Fiera Capital Corp boosted its position in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 20.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,117 shares of the company’s stock after acquiring an additional 4,205 shares during the quarter. Fiera Capital Corp’s holdings in BeOne Medicines were worth $8,557,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Yousif Capital Management LLC acquired a new stake in shares of BeOne Medicines in the 2nd quarter valued at $368,000. Allianz Asset Management GmbH purchased a new position in BeOne Medicines in the second quarter valued at $799,000. DekaBank Deutsche Girozentrale purchased a new position in BeOne Medicines in the second quarter valued at $3,289,000. Asset Management One Co. Ltd. acquired a new stake in BeOne Medicines in the second quarter valued at $4,951,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in BeOne Medicines during the 2nd quarter worth about $28,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeOne Medicines Trading Up 2.2%

ONC opened at $362.14 on Friday. The company has a quick ratio of 2.17, a current ratio of 2.39 and a debt-to-equity ratio of 0.03. BeOne Medicines Ltd. – Sponsored ADR has a 52 week low of $196.45 and a 52 week high of $385.22. The business’s 50 day moving average is $333.08 and its two-hundred day moving average is $328.68. The firm has a market cap of $39.71 billion, a price-to-earnings ratio of 710.08 and a beta of 0.52.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ONC. Royal Bank Of Canada reiterated an “outperform” rating on shares of BeOne Medicines in a report on Wednesday, December 17th. Barclays upped their price target on BeOne Medicines from $385.00 to $394.00 and gave the company an “overweight” rating in a report on Wednesday, February 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a report on Wednesday, January 21st. Sanford C. Bernstein upgraded shares of BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 price objective for the company in a research report on Monday, January 12th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $420.00 target price on shares of BeOne Medicines in a report on Monday, November 17th. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $381.46.

Insider Activity

In other news, CEO John Oyler sold 75,631 shares of the company’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $307.79, for a total value of $23,278,465.49. Following the completion of the sale, the chief executive officer directly owned 24,369 shares of the company’s stock, valued at approximately $7,500,534.51. This represents a 75.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Chan Henry Lee sold 1,660 shares of the stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $349.52, for a total transaction of $580,203.20. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 105,283 shares of company stock valued at $32,463,041 in the last ninety days. 6.62% of the stock is currently owned by company insiders.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.